T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...

Researchers have engineered CAR-T cells armed with computationally designed protein binders that eliminated glioblastoma ...

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

CAR T-cell therapy successfully cleared anti-HLA antibodies to enable kidney transplantation in three highly sensitized ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

Strong initial responses in 4 of 6 patients after many standard drugs had failed ...